Fertility-sparing treatment in early endometrial cancer: current state and future strategies
- Author:
Andreas OBERMAIR
1
;
Eva BAXTER
;
Donal J. BRENNAN
;
Jessica N. MCALPINE
;
Jennifer J. MUELLERER
;
Frédéric AMANT
;
Mignon D. J. M. VAN GENT
;
Robert L. COLEMAN
;
Shannon N. WESTIN
;
Melinda S. YATES
;
Camilla KRAKSTAD
;
Monika JANDA
Author Information
- Publication Type:Review Article
- From:Obstetrics & Gynecology Science 2020;63(4):417-431
- CountryRepublic of Korea
- Language:English
- Abstract: Endometrial cancer (EC) is the fifth most common cancer in women worldwide. Global estimates show rising incidence rates in both developed and developing countries. Most women are diagnosed postmenopausal, but 14–25% of patients are premenopausal and 5% are under 40 years of age. Established risk factors include age and hyperestrogenic status associated with nulliparity, obesity, and metabolic syndrome. Standard treatment for EC, which involves total hysterectomy and bilateral salpingo-oophorectomy, has excellent survival outcomes, particularly for low-grade endometrioid tumors. However, it leads to permanent loss of fertility among women who wish to preserve their reproductive potential. With current trends of reproductive-age women delaying childbearing, rising EC incidence rates, and a growing epidemic of obesity, particularly in developed countries, research on conservative non-surgical treatment approaches remains a top priority. Fertility-sparing treatment predominantly involves the use of oral progestins and levonorgestrel-releasing intrauterine devices, which have been shown to be feasible and safe in women with early stage EC and minimal or no myometrial invasion. However, data on the efficacy and safety of conservative management strategies are primarily based on retrospective studies. Randomized clinical trials in younger women and high-risk obese patients are currently underway. Here, we have presented a comprehensive review of the current literature on conservative, fertility-sparing approaches, defining the optimal candidates and evaluating tumor characteristics, reproductive and oncologic outcomes, and ongoing clinical trials. We have also summarized current guidelines and recommendations based on the published literature.
